Bristol Myers Beats $6.4 Billion Lawsuit Over Delayed Cancer Drug
WEB13 hours ago — (Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug...
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
WEB13 hours ago — Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi and two...
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEB5 days ago — PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults.
U.S. Food and Drug Administration Approves Bristol Myers Squibb…
WEB4 days ago — PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium...
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEBMay 6, 2024 — PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the subcutaneous formulation of Opdivo® (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) (herein referred to ...
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First …
WEBPRINCETON, N.J., March 15, 2024 -- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of...
FDA approves Bristol Myers Squibb's schizophrenia drug
WEB4 days ago — The Food and Drug Administration approved Bristol Myers Squibb’s highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more...
Bristol Myers (BMY) Gets US Nod for First New Schizophrenia Drug …
WEB4 days ago — The medication, to be sold under the name Cobenfy, gained Food and Drug Administration clearance Thursday to treat patients with the illness that often produces hallucinations and delusions.
U.S. Food and Drug Administration Approves Bristol Myers Squibb…
WEB4 days ago — PRINCETON, N.J., September 27, 2024--U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults.
Bristol Myers Squibb Receives U.S. Food and Drug Administration …
WEBAug 21, 2024 — PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Opdivo ® (nivolumab) plus Yervoy ® (ipilimumab) as potential first-line treatment for adult patients with unresectable hepatocellular carcinom...